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The purpose of this study is to evaluate determinants which may be 
important in reactivation of previously drug-treated, inactive cases of 
pulmonary tuberculosis* Since the advent of chemotherapy in the treat¬ 
ment of tuberculosis, reactivation rates of treated cases have declined 
from approximately 25$ in the 19l|0*s to just under 5% at present* Prior 
to the advent of chemotherapy, there were numerous factors which pre¬ 
disposed to reactivation among which the most important were 1) extent 
of disease, (Appendix I), 2) duration of hospitalization, and 3) patient 
cooperation. However, since the widespread use of anti-tuberculosis drugs 
in the treatment of tuberculosis during the past 15 years, little attention 
has been directed to the factor or factors currently leading to reactiva¬ 
tion of disease* 
REVIEW OF THE LITERATURE 
Before the use of chemotherapeutic drugs in the treatment of 
tuberculosis, it was estimated that 15-25$ of cases of pulmonary tuber¬ 
culosis became reactivated. In many reports, however, these data pertained 
more to relapse than to reactivation since these studies included many 
patients who left the hospital and later re-entered before they had become 
inactive according to the present acceptable standards of the National 
Tuberculosis Association. Relapse is, therefore, unfortunately a nebulous 
term that often includes true reactivation but also is used for exacerba¬ 
tion of pulmonary disease that only seemed stabilized. Reactivation for 
the purposes of this study is defined on page 9. 
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of patients in the Herman Biggs Hospital in New York State during the. 
period of 1937-U7. These investigators found that relapse rates correlated 
well with the original extent of pulmonary disease. It was determined 
that during the first 3 years following discharge the relapse rate was 2.9$ 
for UU8 patients with minimal disease] 5*8$ for 22h patients with moderately 
advanced disease] and 10$ for 269 patients with far-advanced disease* These 
patients were not treated with chemotherapy* After 3 years, the rate of 
relapse was 5*3$ for patients with all three categories of disease, i.e*, 
minimal (PI), moderately advanced (P2P), and far-advanced (P3) • These data 
correlate well with other studies which also showed that the greater the 
extent of the original pulmonary disease, the higher the percentage of 
relapse» 
2 
Boyum in Norway in 1958* in a comprehensive review of the world 
literature on relapse, reported some important facts* Boyum reported that 
p 
in the United States a review of 1213 patients by M* G. Stephens during 
the 191U-UU period reported the following relapse rates: in patients; with 
minimal lesions, 28$ of males and 15$ of females relapsed]; in those with 
moderate lesions, 37$ males and 23$ females relapsed] far-advanced lesions, 
Ul$ males and 19$ females relapsed. These data not only demonstrated that 
relapse is more common in the far-advanced group, but also that there was 
a predominance in males in this category. Stephens 1 data also showed that 
2 
relapse was not influenced by age. Other reports (Oyama, 1955 J Mitchell, 
2 
- 1955 ) have shown that relapse was twice as common in patients with bilateral 
disease as compared to those with unilateral disease. However, size of cavi¬ 
tation seemed to have no bearing on relapse. It was also shown by many 
authors (Griep, 19U0 j Stephens, 195U ] Paine, 1951 ) that the longer patients 
















sanatorium, the less likely they were to relapse. 
Boyum^ studied 1*39 cases of relapsed diseases who were admitted to 
one sanatorium in Norway between 19U6 and 1956. All of these patients 
were symptom free from their original disease at the time of their first 
discharge from hospital. He also found relapse more common in patients with 
advanced disease. In patients with bilateral disease, relapse was twice as 
common as those with unilateral disease. Boyum also noted that in the upper 
socio-economic class, the relapse rate was only 2,3% which he attributed to 
better living conditions and freedom from manual labor in the upper socio¬ 
economic group. He also found that men had a slightly greater tendency to 
relapse than womenj and that 75$ of relapses in both sexes occurred during 
the first 5-year period after hospitalization® 
In a current textbook by Walter Page!, Pulmonary Tuberculosis~, various 
factors were mentioned which predispose to activation of a primary focus or a 
secondary clinically inapparent inactive focus, both of which were not pre¬ 
viously treated. These patients are those who are tuberculin positive, but 
who never had clinically apparent pulmonary tuberculosis. Activation of 
disease in these groups is more common in older age groups, and it is 
suggested that such factors as tissue aging, endocrine factors, inadequate 
diet, etc., may be of importance in age distribution. The importance of 
nutrition is emphasized by findings that the rate of tuberculosis in people 
whose weight is only 85$ of normal is lU times greater than those who are 
normal in weight. Endocrine factors also seem to play a role in activation 
of tuberculosis, and it has been recognized that use of steroids increase 
such activation and that the control of tuberculosis infections is more 
difficult in patients having diabetes mellitus® 
The advent of chemotherapy of tuberculosis began in 19U7 with the 
widespread use of streptomycin. This antibiotic was discovered by Schatz, 
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Waksman, and Brigie^ in 19Uii after extensive experimentation with products 
of soil actinomycetes. Streptomyces griseus; produced this product, strepto¬ 
mycin, which was found to be a potent, relatively non-toxic antibiotic. The 
exact mode of action of streptomycin is not known, and at present the most 
generally accepted theory is that it interferes with protein synthesis 
(Davies, et. al., 196l/*') • The activity of streptomycin is both bacterio¬ 
static and bacteriocidal for the tubercule bacillus in-vitro, but in-vivo 
it is mainly suppressive. However, it has been found that when the drug 
is used alone , resistant strains of bacilli develop rapidly,. In addition, 
the drug has the disadvantage of being frequently allergenic j the most 
common manifestations being fever, skin rash, and eosinophilia® 
Also in 19U7, para-aminosalicylic acid (PAS) was introduced in the 
treatment of tuberculosis infection. The mode of action of PAS seems to be 
one of competition with para-aminobenzoic acid (PABA), an essential require¬ 
ment for growth of bacteria* This drug is vised in combination with other 
tuberculostatic drugs mainly streptomycin and isoniazid, since it is very 
ineffective when used alone. Although para-aminosalicylic acid is also 
allergenic, it is less so than streptomycin, and the most important untoward 
reactions with PAS are gastrointestinal symptoms including nausea, vomiting, 
epigastric distress, and diarrhea. Although PAS is closely related chemically 
to the salicylates, it possesses none of the pharmacologic effects of salicylate 
At the present time, the most effective anti-tuberculous drug is 
isoniazid which was first used in 1952® The action of isoniazid has been 
found to be both bacteriostatic and bacteriocidal in in-vitro testing® When 
used alone, resistant strains of bacilli to isoniazid may emerge within a 
few weeks, but this time may vary.' . Also in many cases, even though the 
bacilli are shown to be resisant by in-vitro testing, the efficacy of 
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therapy is not reduced.15*1’ Isoniazid is well tolerated without noticeable 
side effects unless the drug is administered in large doses. The most 
frequent toxic manifestation is that of a peripheral neuropathy which is 
reversed by the administration of Pyridoxine, When isoniazid is used in 
combination with PAS and/or streptomycin, it is a highly effective chemo¬ 
therapeutic agent, and the development of bacterial resistance is delayed 
considerably. 
These three drugs then, isoniazid, PAS, and streptomycin, are the 
major chemotherapeutic agents used in the current treatment of tuberculosis. 
Treatment for pulmonary tuberculosis varies from 1-3 years, the average 
being 2 years. Often after the disease process has been stabilized, PAS 
and streptomycin are discontinued, and chemotherapy with isoniazid alone is 
continued. Clinically, studies have repeatedly shown that when these drugs 
7 
are used properly, treatment failures develop in less than $% of cases. 
Since the advent of chemotherapy in the treatment of pulmonary tubercu¬ 
losis, relapse rates have declined sharply. At the West Haven Veterans 
Hospital, West Haven, Connecticut, P*Esopo, et» al.,v found the observed 
relapse rate over the last ten years to be less than \x%* In a study by 
g 
Phillips at the Kennedy Veterans Hospital, Memphis, Tennessee, in 1961, 
a six-year follow-up of 109 patients showed a relapse rate of 8*5$. In the 
Madras study in Madras, India, the relapse rate of 107 patients who received 
only one year of chemotherapy was only 9%.7 It is now generally accepted 
that approximately 5 per cent of treated cases of pulmonary tuberculosis 
reactivate. 
Many aspects of the treatment of tuberculosis have recently been 
9 10 11 12 13 
investigated at the Tuberculosis Center in Madras, India.' * 3 i * } 
In a recent study at this institution, therapeutic results were compared in 
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regard to home versus sanatorium treatment* Eighty-two (82) Patients, 
U9 males and 33 females, were treated at home and were compared to 
eighty-one (81) patients, 50 males and 31 females, who were treated in the 
sanatorium. Chemotherapy was the same in each group of patients who re¬ 
ceived a mean daily dosage of U,6 mgmsAg of body weight of isoniazid and 
.23 gms.kg of body weight of PAS* It was observed that patients who were 
treated at home received substantially inferior diets compared to those In 
sanatoria. For example, forty-nine per cent of 79 home patients who were 
assessed had a daily calorie intake of less than 2,000 calories compared 
with four per cent of 78 sanatorium patients (Pc 0*001)* At the end of one 
year of treatment, 92$ of the sanatorium patients and 86$ of the home patients 
had quiescent disease, which was defined in this study as negative sputum 
examinations for the last 3 months of treatment. This small difference is 
not statistically significant. After one year of treatment at home and in 
the sanatorium in Madras, 126 patients who had quiescent disease were randomly 
allocated into two groups to be treated at home for one year: one group of 
65 patients received isoniazidj the other group of 6l patients received 
calcium gluconate placebo medication. Results of this study showed that 
isoniazid seemed to have no effect upon relapse of those cases where there 
was persistent cavitation (open negative case), but it was effective in 
preventing relapse in those quiescent cases where there was no residual 
cavitation. In h2 patients with non-cavitary quiescent disease, who were 
treated for an additional one year with isoniazid alone, there were no 
bacteriological relapses. In a similar group of U2 patients treated with 
placebo, there were 5 relapses. This difference is statistically signifi¬ 
cant (Pco05). These results are supported by the results of a combined 
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combined 103 patients with non-cavitary quiescent disease, the relapse 
rate was 0% among those receiving isoniazid and increased to 9% in the 
placebo-treated group*, This is a highly significant difference, (P<0®005)« 
Another group, 60 patients, who had quiescent disease at the end of two 
years and had been treated for two years, were continued on therapy to 
determine the efficacy of 3 years of treatment as compared to 2 years. 
These 60 patients were randomly allocated into two groups of 30 patients. 
At the end of the year, no relapses had occurred in either group. It was 
concluded from these studies that when patients develop quiescent disease 
at the end of one year of treatment with isoniazid and PAS, further isoniazid 
therapy for an additional two years helped to prevent relapses only in those 
patients who did not have residual cavitary disease. The results of the 
five-year follow-up of those patients should provide valuable information® 
Recently, in the United States, Katz, et, al,,^ studied the effect 
of an additional 2 years of isoniazid therapy on inactive previously drug- 
treated cases of pulmonary tuberculosis® These investigators found that 
in 129 previously drug-treated inactive cases, the reactivation rate was 
2*5% as compared to 5*k% in the control group who received a placebo medica¬ 
tion. 
At the present time, no large scale studies concerning factors which 
may play a role in reactivation of pulmonary tuberculosis, treated by 
currently accepted measures, have been conducted. The consensus of opinion 
of many physicians who are working in this field and in particular those 
involved in the Madras study^", is that cure and prevention of reactivation 
is dependent on four factors: 1) adequate chemotherapy, 2) duration of 
chemotherapy, 3} patient cooperation, and h) initial drug sensitivity^ and 
conversely, reactivation seems to be independent of age, sex, and extent of 
disease® 
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MATERIALS AND METHODS 
This project consists of a follow-up study of i|Q reactivated cases of 
pulmonary tuberculosis and UG-non-reactivated control cases who were selected 
from the records of the Mt. Morris Tuberculosis Hospital in Mt. Morris, 
New York. Mt. Morris Hospital is located in western New York state and 
presently serves the entire western part of the state, encompassing 15 counties* 
This hospital has a capacity of 350 beds and presently the average census is 
approximately 250 patients. The hospital is staffed by ten physicians, two 
surgeons, a part-time pathologist, a full-time radiologist, and a fully 
equipped laboratory* The out-patient department primarily serves Livingston 
County through the hospital and in addition the staff visits a major city 
in the ten outlying counties on a monthly basis. 
All new cases admitted to the hospital are presented to the director 
and the medical staff of the hospital. X-rays are reviewed by the hospital 
radiologist and are again considered when the case is presented to the 
medical, staff. Decisions regarding chemotherapy, activity of disease, and 
hospital discharge of patients are made at weekly staff conferences, where 
x-rays are again reviewed. 
In this study, all diagnoses dependent upon radiologic interpretation, 
i.e* , emphysema, silicosis, and cavitary lung lesions Twere reviewed at my 
request with a member of the house staff or the director. This procedure 
was followed in all cases of emphysema, silicosis, and in those cases 
reported as questionable cavitary lesions. In most cases, diagnosis of 
emphysema was a combination of clinical and radiologic interpretation, for 
there were no pulmonary function tests performed in mose cases. 
CRITERIA FOR SELECTION OF STUDY GROUP AND CONTROLS 
To be included in this study, the reactivated patients must have been 
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hospitalized and treated with chemotherapy for control of their pulmonary 
tuberculosis. They then must have reached an inactive status defined by 
the National Tuberculosis Association which specifies? 1) a negative sputum 
examination for a minimum period of 6 months, 2) a stable chest x-ray for a 
minimum period of 6 months, and 3) no evidence of pulmonary cavitation or 
bronchopleural fistulae (see Appendix II). The diagnosis of pulmonary 
tuberculosis was made on the basis of 1) a positive sputum culture (human 
M. Tuberculosis var hominis), 2') radiologic evidence of pulmonary tuberculosis, 
and/or 3) a compatible clinical picture. All patients were treated with 
chemotherapy, either with a program consisting of isoniazid and adjuvant 
drugs, or with a program without isoniazid, which included mainly PAS and 
streptomycin. The majority of these patients were initially treated at 
Mt. Morris, although a few were treated at other regional hospitals* All 
patients were followed in the Mt. Morris out-patient department* Because 
of the difficulty in selecting cases considered to be true reactivations of 
pulmonary tuberculosis, the L'O patients in this test group are the only true 
reactivated cases which could be uncovered in a review of records of the 
Past 15 years at Mt. Morris Hospital* 
The most important criterion of reactivation of pulmonary tuberculosis 
is the development of a positive sputum examination after previously demon¬ 
strated inactivity of the tuberculous infection. In most cases in this study, 
patients developed two or more positive sputum examinations and demonstrated 
recent x-ray changes and/or associated clinical symptoms. In these few cases 
where there was only one positive sputum examination, it was necessary that 
radiologic changes and/or clinical symptoms be demonstrated in order to 
consider the patient as having reactivated disease. Therefore, a patient 
having only a single positive sputum examination without additional evidence 
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of disease was not considered to be a reactivated case because this 
situation could represent a laboratory error or a chance finding* and it is 
probably neither clinically nor epidemiologically important. All study 
patients reactivated within five years after reaching the inactive status» 
The matched control group is composed of persons* who like the study 
group* had developed pulmonary tuberculosis diagnosed on the basis of the 
following criteria? 1) a positive sputum examination* 2) radiologic evidence 
and/or 3) associated clinical picture <» These patients had also been 
treated with hospitalization* chemotherapy and in some cases resectional 
surgery. The control patients had reached an inactive status and had remained 
so for at least five years* They were also followed regularly in the out¬ 
patient department of Mt. Morris Hospital and had received at least yearly 
chest x-rays and sputum examinations* In all control cases, sputum exam¬ 
inations remained negative and the x-ray findings revealed no essential 
changes* If, as was the case in a few individuals, radiologic change was 
demonstrated, but this was not associated with the demonstration of a 
positive sputum examination, the patient was still considered to have 
inactive disease* 
SELECTION OF PATIENTS AMD CONTROLS FOR STUDY AND COLLECTION OF INFORMATION 
Patients with reactivated pulmonary tuberculosis; were selected for 
this study by a review of all hospital records of the Mt* Morris Tuberculosis 
Hospital during the past 1$ years. Cases were reviewed by first examining 
the discharge index card on each patient and then reviewing the correspond¬ 
ing chart. Controls were selected by also reviewing the discharge Index 
cards. The control patients were included in the study by matching with 
the study group patients in five categories: 1) age, 2) sex, 3) race, 
U) use of resectional surgery* and 5) presence or absence of isoniazid in 
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the chemotherapy regimen, and if they had a five-year follow-up study 
confirmed by continuing inactivity. No other factors were considered in 
selecting the control patients. The records of each patient were reviewed 
through the use of a 12-page information sheet as a basic outline for 
obtaining information® The areas that were investigated can be divided 
into three main areas:: 1) the general characteristics, history, and 
admission data, 2) observation in the hospital, and 3) observation after 
discharge from the hospital. The areas that were emphasized in this study 
pertained to length of hospitalization, length of active disease, sputum 
culture patterns, conversion time under chemotherapy, the amount and length 
of drug therapy, and the post discharge conditions® The results obtained 
in these areas of study and others are reported and discussed in this 
paper. 
In this study, there were no patient interviews, and all information 
was gathered from the written record® The hospital course of the patient 
was only discussed with the physician in charge when the written record 
was unclear® This procedure, however, was not often necessary because the 
records at Mt. Morris Hospital are typewritten and follow a standard format® 
RESULTS 
GENERAL CHARACTERISTICS, HISTORY, AND ADMISSION DATA OF STUDY AND CONTROL GROUPS: 
The reactivated and control groups are composed of UO patients each* 
The characteristics of these cases by age are recorded in Tables 1 and 2® 
The s tudy group of reactivated cases and control group were matched in 
five categories: 1) age, 2) sex, 3) race, U) use of resectional surgery, 
and £) presence or absence of isoniazid in the chemotherapy regimen. 
The age in years designated for each patient is the age at which 
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57.0? years with a range of 20 to 88 years while the control group had 
a mean of 55*62 years with a range of 16 to 75 years. 
In regard to marital status, as depicted in Table 3, 10 patients 
(25$) in the study group were either divorced or separated. In the control 
group, 5 patients (12.5$) had been either divorced or separated. However, 
this finding was not statistically significant (P=„lU)„ 
Patients in both groups were evaluated for concomitant disease which 
was present prior to the time they developed tuberculosis and persisted 
during the treatment of their pulmonary tuberculosis. Many of these 
disorders are chronic diseases, and there was no reliable way to determine 
their severity in an objective fashion. The diagnosis of concomitant 
disease was made by the examining physician at the time of admission or 
by appropriate tests performed during the hospital course. Those patients 
with emphysema and silicosis were reviewed radiologically for evidence of 
disease. Unfortunately, no pulmonary function tests were available for 
most of these patients. As shown in Tables U and 5* 13 patients (32.5$) in 
the study group had pulmonary emphysema whereas, 10 patients (25.0$) in the 
control group had pulmonary emphysema. The prevalence of diabetes mellitus,, 
silicosis, or extra-pulmonary tuberculosis was the same in both the study 
and control groups. 
All patients were evaluated for the presence or absence of respiratory 
symptoms of tuberculosis at the time of admission to the hospital. These 
symptoms included cough, shortness of breath, chest pain, hemoptysis, etc. 
In the study group, 35 patients (90$) had respiratory symptoms whereas, 
32 patients (80$) in the control group had such symptoms. 
A past history of tuberculosis'documented by positive sputum, clinical 
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In none of the patients had anti-tuberculous chemotherapy been used* Ten 
patients (25$) in the study group had a past history of tuberculosis whereas, 
in the control group 7 patients (17^) had a positive history. This information 
regarding previous tuberculosis infection was obtained by the admitting physi¬ 
cian and in some cases by clinical reports from other hospitals which were 
forwarded to Mt. Morris Hospital. In general, however, the information lacked 
specificity and no meaningful comparisons could be made between patients in both 
groups in regard to duration of past episodes, time between last clinically 
evident tuberculosis and present tuberculosis, etc* 
When patients are admitted to the hospital, the extent of their pulmon¬ 
ary disease is determined by ra.diologic examination. The extent of disease 
is determined in accordance with NTA definition (see Appendix I), and is 
classified as minimal (PI), moderately advanced (P2), or far-advanced (P3)» 
Radiologic examinations also determine the presence or absence of cavitation. 
If cavitation is present, the extent of disease is considered to be at least 
moderately advanced (P2). Patients in both groups were classified in this 
study in relation to the extent of their disease according to the most 
advanced extent attained and were compared. As depicted in Table 6, both 
study and control groups had a similar number of cases having minimal, 
moderately advanced, and far-advanced disease.. 
The presence of bilateral and unilateral pulmonary disease was also 
compared in both groups. It was noted that bilateral disease was present 
in 25 patients (62.5$) in the study group and in 27 patients (67.5$) in the 
control group. These results are shown in Table 7. Cavitary disease was 
present in 20 patients (50$) in the study group and in 19 patients (1i7.5$) 
in the control group as shown in Table 8. 
Due to the lack of specific information, patients were not compared in 
regards to occupation, smoking habits, drinking habits or educational background. 
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OBSERVATIONS©? HOSPITALIZED PATIENTS AND CONTROLS 
A. DAYS OF HOSPITALIZATION 
In regard to the number of days of hospitalization, it was found that 
the UO study cases were hospitalized for periods ranging from 65 to 3?h0 
days with a mean of h79 days* Similarly, the control group was hospitalized 
for intervals of 35 to 2070 days with a mean of U77 days. There is no 
significant difference between the two groups. 
It is recognized, however, that for a variety of reasons in-patients 
hospitalization treatment of cases of pulmonary tuberculosis is not always 
continuous and patients may leave the hospital temporarily for a variety of 
reasonso For the purpose of these analyses, a break in continuity of 
hospitalization is defined as a period of time of greater than 10 days away 
frcm the hospital. In the study group, 6 patients (1 woman and 5 men) or 
15$ were absent from the hospital while their disease was active. These 
absences ranged from 30 to 510 days with a mean of 18U days. During this 
time, however, only one patient (a 66-year old man) discontinued chemotherapy! 
and this was for a period of 2U0 days. Among the U0 control patients, 5 men 
(12.5$) were absent from the hospital for intervals ranging from 21 to 60 days 
with a mean of 37 days. During these absences, all 5 patients discontinued 
chemotherapy. 
B. ACTIVITY OF DISEASE 
The length of time that the disease remained active was evaluated in 
each group. Active disease is defined as the length of time between the 
first positive sputum or the onset of synptoms which later were proved to 
be those of tuberculosis, and the inactive disease status. In the study group 
of reactivated cases, patients were active a mean of 68U days with a range 
of 200 to 2785 days. The control group was active for 67U days with a 
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range of 200 to 2190 days. There is no significant difference between 
the two groups. 
The mean length of time between the first positive sputum examination 
and the last positive sputum examination was also calculated for each group0 
The study group had a positive sputum for a mean of 362 days with a range of 
10 to 2U0Q days. The control group was positive for 296 days with a range 
of 10 to 1800 days. This difference of 93 days is not statistically 
significant.(P=,38). 
A more critical examination of the length of sputum positivity is 
the time interval of conversion from positive to negative during chemotherapy. 
In each group, the mean average number of days from the beginning of cherno- 
therapy to the last positive sputum was calculated. The conversion time 
under chemotherapy in the study group was 226 days with a range of 10 to 
2h00 days and was 179 days in the control group with a range of 10 to 1155 
days. This difference of b7 days is not statistically significant.(P=.62)• 
C. TREATMENT WITH ANTI-TUBERCULOSIS DRUGS 
The total number of days of chemotherapy was tabulated for patients in 
both groups. This included chemotherapy of any type which was administered 
during a patient's hospitalization as well as during follow-up study in the 
out-patient departments. Chemotherapy was received by the study group for 
a mean of 698 days with a range of 128 to 3170 days and by the control group 
for a mean of 766 days with a range of 251 to 3285 days. This difference of 
67 days is not statistically significant. (Peo62)„ 
Continuity of chemotherapy including both hospital and out-patient 
department treatment was also studied. In the study group, of reactivated 
cases, 3 patients (7*5/0 discontinued chemotherapy for periods ranging from 
10 to 2U0 days with a mean of 130 days. In the control group, 7 patients 
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(17.5%) discontinued chemotherapy for periods ranging from 15 to 575 days 
with a mean of 110 days. 
The amount of isoniazid received by reactivated and non-reactivated 
cases was calculated and compared. In each group, 35 of U0 patients re¬ 
ceived isoniazid in their chemotherapy regimen. Isoniazid administered in 
the hospital as well as at home was combined to obtain the total amount of 
isoniazid which had been received by each patient. In almost all cases, 
the patients were also taking other drugs, mainly PAS and/or streptomycin. 
It was found that the study group received a total mean dosage of 202.9 
grams of isoniazid with a range of 38 to 1021 grams while the controls 
received a mean dosage of 189.5 grams of isoniazid with a range of 13 to 
518 grams. This difference of 13.h grams is not statistically significant, 
(P=.72), It was interesting that there is no significant difference between 
these two groups, but not surprising, since the average number of days of 
chemotherapy is similar in both groups. 
D. INDEX OF THERAPEUTIC RESPONSE TO TREATMENT 
WEIGHT GAIN. The parameter of weight gain was examined in each group 
and used in this study as an index of response to treatment. Each patient 
liras weighed monthly to evaluate the progress of his clinical course. At the 
time of discharge, the group of reactivated cases had gained a mean of 12.lt 
pounds with a range of 0 to 53 pounds. In contrast, the control group had 
a mean weight gain of 20.1 pounds with a range of 0 to 6l pounds. This 
difference of 7.7 pounds is statistically significant (P <:.01). However, 
there was no knowledge of the patient's ideal body weight in relation to the 
amount of weight gained nor was height recorded. As shown in Table 9, 
3 patients in the study group failed to gain weight and no information was 
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available on 7 patients; in the control group, 2 patients failed to gain 
weight, and there was no information on 2 patients. 
PERCENT OF SPUTUM POSITIVITY. In the study group, an attempt was made to 
develop an index of clinical findings which might alert the physician to the 
possibility of reactivation of pulmonary tuberculosis infection. Accordingly, 
patients were studied in relation to patterns of sputum positivity. At the 
Mt, Morris Hospital, sputum cultures are collected for three consecutive days 
following the admission of each patient and usually once monthly thereafter. 
Since all patients in each group eventually became inactive, their sputum nec¬ 
essarily converted from positive to negative. In an attempt to determine the 
pattern of final sputum conversion from positive to negative, the percent of 
positive sputum cultures was calculated for each individual to classify his 
conversion pattern. The percent of positivity is the ratio of the number of 
positive cultures from the first positive to the last positive culture to the 
total number of cultures collected from the first positive to the last positive 
culture. For example, if a patient had his first three cultures positive and 
then remained negative for the remainder of his sputum examinations, the percent 
of positivity would be 3 positive cultures over 3 total cultures from the first 
positive to the last positive, or 100$* On the other hand, if a patient had 
his initial 3 cultures positive and then had 5 monthly negative cultures 
followed by 1 positive culture before his sputum became repeatedly nega¬ 
tive again, his percent of positivity would be h/9, or hh%» It is apparent 
that for this index to have meaning, regular sputum cultures must be 
performed so that equal time intervals are present between examinations. 
For example, at the end of ten months of treatment, each patient should 
have had recorded three initial sputum examinations and nine subsequent 
monthly examinations. This exemplified pattern was recorded for most patients, 
but there probably were some exceptions that were not carefully evaluated 
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when this information was collected. Thusly, conclusion obtained from these 
results can be questioned. 
Each patient in both study and control groups was evaluated for the 
percent of sputum positivity and the results are summarized in Table 10. 
According to this analysis, 13 patients (32.5$) in the study group had a 
percent of positivity of less than 75% whereas, in the control group only 
5 patients; (12.5$) had a percent of sputum positivity of less than 75$* The 
difference of 20% between the two groups is statistically significant.(P-.03)* 
CLINICAL COURSE OF STUDY AND CONTROL GROUPS FOLLOWING HOSPITALIZATION 
A. CONDITIONS FOR DISCHARGES FROM HOSPITAL 
At the Mt. Morris Hospital, the conditions for discharge of a patient 
can be considered in 5 categories: 1) maximum hospital benefit (MHB)j 
2) personal reasons with or without consent of the clinical staffj 3) against 
medical advice (AMA) j U) absent without authorized leave (AWOL)j and 
5) disciplinary reasons. It was found in this study that 35 patients 
(87*5$) of the study group and 3h Patients (85*6$) of the control group 
were discharged with maximum hospital benefit. These findings are depicted 
in Table 11. 
B. ACTIVITY OF DISEASE AT TIME OF DISCHARGE 
At the time of discharge from the hospital, 19 of UO patients (h7%) of 
the study group were considered to have inactive disease whereas, in the 
control group, 16 of UO patients (U0$) were inactive at discharge. These 
results are shown in Table 12. No difference was observed in the age 
distribution of these two groups nor was there appreciable difference in the 
prevalence of emphysema or other concomitant disease. 
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C. USE OF CHELIOTHERAPY ON DISCHARGE 
When patients are discharged from the hospital they often continue 
chemotherapy for some time as an outpatient* It was shown that In the study 
group only 7 patients (±7*5%) could be discharged without further chemo¬ 
therapy whereas, in the control group lU patients (35%) could be discharged 
without further chemotherapy* This difference is not statistically signifi¬ 
cant. (P~.08)* Of the 7 patients in the study group who were discharged 
without further chemotherapy, it was found that 6 of these 7 patients (Q5%) 
had Inactive disease* Similarly, in the control group, of the lb patients 
discharged without further chemotherapy, it was found that 12 of these 
lb patients (85%) had inactive disease* These findings suggest that discon¬ 
tinuation of chemotherapy at discharge may mean inactive disease; however, 
it cannot be concluded that the converse, i*e*, that inactivity of the 
infection at discharge of the patient implies discontinuation of therapy, 
is true. This point is shown in Table 13 which compares inactivity of 
disease at discharge to discontinuation of chemotherapy* In the study group, 
19 Patients (b7»5%) were inactive at discharge and in control group 16 patients 
(h0%) were inactive at discharge* However, in the study group, only 6 of 
these 19 inactive patients; (3&<>5%) were discharged without further chemotherapy 
whereas, in the control group 12 of 16 inactive patients (75%) were discharged 
without further chemotherapy* This difference of 38»5% Is statistically 
significant.(*02< P <.05)• This comparison is shown in the following graph. 
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GRAPH NO. 1 
COMPARISON OF INACTIVE DISEASE STATUS 
AND DISCONTINUATION OF CHEMOTHERAPY IN PATIENTS HAYING REACTIVATED 
PULMONARY TUBERCULOSIS AND CONTROLS. 
Total number of patients discharged with inactive 
disease® 
Total number of patients discharged with inactive 
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Such differences suggest that inactive disease status at discharge was associ¬ 
ated with discontinuation of chemotherapy in the control group, but for some 
reason inactivity at discharge was not associated with discontinuation of 
chemotherapy in the study group. 
An attempt was made to evaluate patients’ adherence to discharge 
recommendations, Although this was a subjective evaluation and no apparent 
disregard for discharge recommendations in various categories was found in 
either group. The most objective parameter which could be evaluated was 
whether patients took their prescribed chemotherapy, and even this was often 
difficult to determine. In the study group, 8 patients (20$ failed to continue 
their recommended chemotherapy while 6 patients (12.5$) in the control group 
failed to continue. 
D. USE OF CHEMOTHERAPY AFTER THE INACTIVE STATUS 
The number of days of chemotherapy after patients had reached the 
inactive status was calculated for each group. Most patients received their 
chemotherapy after becoming inactive through the outpatient department of the 
hospital. The mean number of days of use of chemotherapy after the inactive 
status in the study group was 1?6 days with a range of 0 to 820 days and in the 
control group was 215 days with a range of 0 to 2000 days. This difference of 
39 days is not statistically significant (P=.60). In the study group, 10 
patients (25$) received no chemotherapy after they became inactive, and in the 
control group 15 patients (37•5$) received no chemotherapy after they reached 
the inactive status. This difference also is not statistically significant 
(P=.22). 
E. TIME OF REACTIVATION OF DISEASE 
In the study group, it was found that reactivation of disease occurred 
on the average 660.50 days after the inactive status with periods ranging 
from 60 to 1800 days. 
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DISCUSSION 
Prior to the advent of chemotherapy, there were numerous factors 
which predisposed to reactivation of pulmonary tuberculosis, the most 
important being: 1) extent of disease, 2) duration of hospitalization, and 
3) patient cooperation. It has been shown in numerous studies that reactiva¬ 
tion and relapse were more common the more advanced the extent of pulmonary 
1 2 
disease . It was also shown that patients having bilateral pulmonary 
disease relapsed more frequently (twice as common) than did those with 
2 2 
unilateral disease » Relapse also seemed to be independent of age * 
However, since the widespread use of anti-tuberculosis drugs during the 
Past 1$ years, little recent attention has been directed to the factor or 
factors currently leading to reactivation of cases of pulmonary tuberculosis* 
treated -with these agents* 
In this study, it has been possible to compare certain factors which 
may play a role in reactivation of pulmonary tuberculosis in a group of 
hO patients and UO matched controls in whom reactivation of disease did not 
occur* These two groups were matched in $ categories: 1) age, 2) sex, 
3) race,, U) presence or absence of isoniasid in chemotherapy regimen, and 
5) use of resectional surgery* 
In an attempt to correlate all the factors that have been compared, 
it is difficult, if not impossible, to delineate the factor or factors 
responsible for reactivation of previously drug-treated inactive pulmonary 
tuberculosis* The differences in those areas which were compared were in 
most cases not statistically significant, but there were several statistically 
significant differences. 
In interpreting the significant results of this study, it is assumed 
that the patients in each group were essentially of the same background] 
-22- 
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had similar disease; and received essentially similar standard treatment* 
The results, as well as can be interpreted, substantiate these assumptions* 
In regards to previous history, it was found that there was no significant 
difference between the groups in the presence of concomitant disease, 
respiratory symptoms on admission, past history of tuberculosis, marital 
status, extent of tuberculous infection, or presence of pulmonary cavitation* 
There were also no significant differences in the number of days these 
patients were in the hospital, the continuity of their hospitalization, the 
total time of their active pulmonary disease, the total time of sputum 
positivity, the time of sputum conversion under chemotherapy, the total 
days of chemotherapy received, the continuity of chemotherapy, the amount of 
isoniazid therapy which they received, and the number of days of chemotherapy 
which they were given after reaching an inactive status* It is also assumed 
that t he patients in both groups received a similar diet while in the 
hospital* 
In terms of the objectives of this study, the findings indicate that 
weight gain in the hospital may he a reliable prognostic index concerning 
subsequent reactivation, of pulmonary tuberculosis infection. Gain in body 
weight can also be interpreted as an index of clinical response to treatment* 
It was found that at the time of discharge after an equal time in the 
hospital, with a similar diet, the study group of reactivated cases had 
gained a mean of 12*1; pounds with a range of 0 to 53 pounds while the control 
group gained a mean of 20.1 pounds with a range of 0 to 6l pounds. This 
difference of 7»? pounds is statistically significant (P < .01). This 
difference suggests that the clinical response was different in the two 
groups even though patients in each group attained an inactive status in 
a similar time. Inactive disease status is based on radiological and 
-23> 
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bacteriological information rather than clinical impression,, 
L ^1 
In the Madras study , certain facts were obtained regarding diet and 
weight gain. In comparing patients treated at home and in the hospital, it 
was found that although there were obvious measurable difference in the 
quality of their diets, there was no difference in attaining quiescent 
disease status at the end of one year. However, bacteriological conver¬ 
sion to negativity did occur more rapidly in the sanatorium patients. The 
average weight gain for a 12-month period was 19*8 pounds for the sanatorium 
patients and 10.8 pounds for the home patients. This difference of 9 pounds 
seems to be significant but not associated with differences in clinical 
response at the end of one year. However, in the present study, it is 
assumed that the diet in each group was similar with no obvious discrepancies 
as there was in the Madras study, and thus, the failure of the reactivated 
group to gain weight can be interpreted as an inadequate clinical response 
rather than an inferior diet. Thus, using weight gain as an index of the 
clinical response to treatment, it can be concluded that in this study, the 
control group of non-reactivated cases did have a better clinical response 
than did the study group of reactivated patients* 
Another finding which suggests a poor clinical response to treatment 
is the comparison of the status of disease activity and the continuation 
of chemotherapy at the time of discharge. As was shown in the results, it 
seemed initially that inactive disease at discharge was an important criteria 
for discontinuation of chemotherapy. However, when the number of patients 
who were inactive at discharge is compared to the number of patients who were 
allowed to discontinue chemotherapy, certain differences were observed. In 
the study group, 19 patients were discharged with inactive disease but in 
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only 6 (36$) of these 19 patients was chemotherapy discontinued. In 
the control group, 16 patients were considered to be inactive at discharge, 
and in contrast to the study group, 12 (75%) of these 16 patients were 
permitted to discontinue chemotherapy. This 38.5$ difference is statis¬ 
tically significant (.02<P C.0$). It can be concluded that although 
almost half of the reactivated patients were inactive at discharge, the 
clinical staff at Mt, Morris Hospital discontinued chemotherapy in only 
36$ of these patients whereas, in the control group 75$ of 16 inactive 
patients were discharged without further chemotherapy. The reason for the 
continuation of chemotherapy in the study group patients is not clear, 
however, it can be hypothesized that clinical evaluation of the response of 
the patients to treatment was such that continuation of chemotherapy was 
deemed necessary. 
Another parameter which may be used to determine clinical response is 
the percent of sputum positivity. As explained previously, this is the ratio 
of the number of positive sputum cultures to the total number of cultures 
taken from the first positive culture to the last positive culture. In this 
study, 13 patients (32.5$) among reactivated patients had a sputum positivity 
ratio of less than75$ whereas, in the control group only 5 patients (12*5$) 
had a sputum positivity ratio of less than 15%» This difference of 20% was 
found to be statistically significant (Pi .03). These observations suggest 
that the patients whose disease later became reactivated converted their 
sputum to negativity in a sporadic manner and showed a pattern of positive 
sputum cultures intermixed with negative sputum cultures. On the other hand, 
the control patients generally seemed to convert to negative and remained 
so without demonstrating intermittent positive sputum cultures. This may 
mean that the reactivated group did not respond to treatment as completely 
-25 
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as the control group even though both groups converted to negativity under 
chemotherapy during the same time period. The limitations of the collection 
of the data pertaining to the percent of sputum positivity was mentioned in 
the results; however, if further study in this area proved the validity of 
the percent of sputum positivity, the value of this observation as prognos¬ 
tic aid would be greatly increased® 
An evaluation of the utilization of chemotherapy in this study 
revealed that there was no significant difference in the number of days of 
chemotherapy which each group received; likewise, the total amount of 
isoniazid received by each group was similar® Katz." u found that treatment 
with isoniazid alone, which was continued for two years after inactivity, 
lowered the reactivation rate in 129 patients to 2.5% in the study group 
compared to 5% in the controls. In the Madras, India, study, it was shown 
that isoniazid alone administered for one year after quiescence in patients 
having no residual cavitation, helped to prevent relapse. In 103 patients 
with non-cavibating, quiescent disease, the relapse rate was 0% in the 
isoniazid group and 9% in the placebo-treated group (P <.005). However, 
it was also shown that treatment with isoniazid alone for 2 years after 
quiescence was no more efficacious than 1 year of treatment after quiescence 
of active disease. This was demonstrated by treating 30 patients and 30 
controls with isoniazid and placebo; in both groups, the relapse rate was 0%. 
It has not been shown in any retrospective study that reactivated patients 
received significantly less chemotherapy than control patients. 
In the present study, there were numerous host and environmental factors 
which were common to both groups. In this regard, it was of interest that 
there was an equal distribution of the extent of disease (P-j , Pg, P^) in 
each group. This contrasts sharply to the findings during the pre-chemotherapy. 
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era where it was clearly shown that relapse was dependent upon the extent 
of disease and occurred much more frequently in those patients with far- 
advanced disease. However, in the present study, since patients were 
matched for age, reactivation seemed to be independent of extent of disease 
only among individuals of similar age. 
Another finding related to the extent of disease is the presence or 
absence of pulmonary cavitation. These differences as well as the presence 
of bilateral pulmonary disease were equally distributed between both groups 
and had no apparent effect upon reactivation of disease. 
In this study, the length of hospitalization was similar in both 
reactivated patients and controls<> Also, there was no difference in the 
prevalence of concomitant disease in both groups which included emphysema, 
silicosis, diabetes mellitus and extra-pulmonary tuberculosis. This result 
can be questioned because there was no way of comparing the severity of any 
of these diseases* 
Among the factors which were not possible to study in this group of 
patients, several of importance deserve mention. The first is determination 
of the drug sensitivity of the infecting strain of tubercle bacillus* Sensi¬ 
tivity of the organism to the major antituberculosis drugs is known to be a 
factor in the therapeutic response to treatment and is thought to be a factor 
1^ 
in relapse of the disease . In this study, the drug sensitivity was not 
known in many cases, and thus could not be evaluated. It is also known 
that often patients respond to the prescribed drug although the in vitro 
17 
sensitivity test shows the organism to be resistant to the drug 1 It 
has also been observed that a single sensitivity test may show the organism 
to be resistant whereas, a subsequent test may indicate sensitivity, thus 
making the interpretation of the conflicting data quite difficult. 
Another area which could not be accuately evaluated because of lack of 
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information was the home environment and events in the lives of the patients 
after discharge from the hospital. Even though in most cases, the patients 
were followed in the outpatient department, no objective evaluation could be 
made regarding the patients’ environment. Additional study of environmental 
influences on a patient’s disease may provide some important leads in the 
study of reactivation of adequately treated cases of pulmonary tuberculosis. 
SUMMARY AMD CONCLUSIONS 
1. The purpose of this study is to evaluate determinants which may be import¬ 
ant in reactivation of previously drug-treated inactive cases of pulmonary 
tuberculosis. This is a retrospective study of I4O reactivated patients and 
UO control patients. Both groups had pulmonary tuberculosis, were drug-treated, 
and reached the inactive status. The study group patients reactivated within 
a five-year period and the controls remained inactive for at least five years. 
The two groups were matched in five categories.* 1) age, 2) race, 3) sex, 
I4) use of resectional surgery, and 5) presence or absence of isoniazid in 
the chemotherapy regimen. Since these areas were matched, they could not be 
compared and evaluated. Also not evaluated because of lack of information 
was occupation; smoking habits; drinking habits; educational background; an 
objective evaluation of the patient’s life after becoming inactive; and most 
important, drug sensitivity of the organism. 
2'. There was a significant difference in weight gain during hospitalization 
between the two groups: the reactivated study group gained 12.U pounds 
whereas, non-reactivated controls gained 20,1 pounds. This 7.7-pound differ¬ 
ence is statistically significant (Pk.01). 
3. In the group of reactivated cases, 19 patients were discharged with 
inactive disease but in only 6 (36$) of these was chemotherapy discontinued. 
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In the control group, 16 patients were discharged with inactive disease but 
in contrast to the reactivated cases, 12 (75$) of these 16 patients were 
advised to discontinue chemotherapy* This 38*5$ difference was found to be 
significant (.02 2 p -2.05) * 
ho In the study group, 13 patients (32*5$) bad a percent of sputum 
positivity of less than 75$ whereas, in the control group only 5 patients 
(12*5$) had a percent of sputum positivity of less than 75$* This 
difference of 20$ is statistically significant (Ps .03). 
5* No differences of significance were found between the reactivated and 
control groups in the following areas: extent of disease; presence or 
absence of cavitating lesions; concomitant disease; marital status; past 
history of tuberculosis; duration of hospitalization; continuity of 
hospitalization; total duration of active disease; total time of positive 
sputum; conversion time to negativity under chemotherapy; days of chemo- 
therapy; continuity of chemotherapy; amount of isoniazid administered; 
reason for discharge; adherence to discharge medical recommendations; and 
days of treatment after attaining an inactive status. 
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TABLE NO. 1 
AGE, SEX AND RACIAL CHARACTERISTICS OF 





































< 30 3 
r" 
7*5 2 5 0 0 1 2.5 0 0 
30-39 3 7.5 2 5 1 2.5 0 0 0 0 
U0-U9 5 12,5 2 5 1 2.5 2 5.0 0 0 
90-59 11 27.5 8 20 1 2.5 2 5.0 0 0 
> 60 18 1*5.0 j 17 1*2.5 0 0 1 2.5 0 0 
TOTALS 1*0 100 31 77*5 3 7.5 6 15.0 0 0 
* Age determined at time of inactivity* 
° Reactivated cases* 
. 
■ 
TABLE NO. 2 
USE OF RESECTIONAL SURGERY AND CHEMOTHERAPY WITH ISONIAZID IN 
PATIENTS HAVING REACTIVATED PULMONARY TUBERCULOSIS AND CONTROLS 
1 Resectional Surgery in 
Patients in Study and 
Control Group 
Patients with INH in 
Chemotherapy Regimen 
in Study0 and Control 
Groups 
Age in 
Years No. ] 
No,with 








< 30 3 0 0 3 7.5 3 
_ 
7.5 0 0 
30-39 3 2 5.o 1 2.5 i 2 5.0 1 2.5 
U0-U9 5 2 5.0 3 7.5 3 7.5 2 5.0 
50-39 11 2 5.o 9 22,5 10 25.0 1 2.5 
> 60 18 0 0 18 i*5.o 17 1*2.5 1 2.5 
TOTALS UO 
6 
15*0 3k 85.0 35 87.5 5 12.5 
*Age determined a^ time of inactivity, 
oReactivated cases. 
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TABLE MO. 3 
COMPARISON OF MARITAL STATUS AMONG MALES AND FEMALES HAVING 
REACTIVATED PULMONARY TUBERCULOSIS AND CONTROLS. 
Patients with Reacti- Control Group 
vated Disease Patiei nts 
Marital Status Male Female Male Female 
No. % No. % No. % No. % 
Single 8 20.0 3 7.5 10 25.0 3 7.5 | 
Married 11* 35.0 1 2.5 
| 
11* 35.0 3 7.5 I 
Separated 
1 




3 7.5 0 0 3 7.5 0 0 
1 
Widowed 3 7.5 1 2.5 5 12.5 0 0 
1 TOTALS 
L _ 
3h 85.0 6 15.0 3h 85.0 j 6 15.0 
NOTE: 
Percentage of divorced and separated patients in study and controls: 
Study patients 25.0$ 
Control patients 1205% 
Standard error of the difference - 8.6 
Observed difference/standard error of difference 12.3/8.6 = 1.1*6 
P value - .11* 
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TABLE NO. h 
PREVALENCE OF PULMONARY EMPHYSEMA AND CONTROL IN 
patients having reactivated pulmonary tuberculosis and controls. 




























< 30 3 0 0 0 0 3 7.5 3 7.5 
30-39 3 0 0 0 0 3 7.5 3 7.5 
U0-U9 5 1 2.5 1 2.5 h 10.0 h 10.0 
50-59 ll 3 7.5 5 12.5 8 20.0 6 15.0 
> 60 18 9 22.5 h 10.0 9 
I 
22.5 1U 35.0 
TOTALS hO 13 32.5 10 j 25.0 27 67.5 30 75.0 
*Age determined at time of inactivity. 
^Reactivated cases® 
NOTE: 
Observed difference of 7.5$ (32.5 - 25.0) is not statistically 
significant. 
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TABLE NO. 5 
PREVALENCE OF DIABETES MELLITUS, SILICOSIS, AND EXTRA-PULMONARY 
TUBERCULOSIS IN PATIENTS HAVING REACTIVATED PULMONARY TUBERCULOSIS AND ‘CONTROLS * 
Associated Disease Process Study^Grou] d Patients Control Group Patients 
No® % No® % 
Diabetes Present 1 2.5 5 12.5 
Mellitus 
Absent 39 97.5 35 87.5 
Silicosis Present 2 5.0 3 7.5 
Absent 38 95.0 3? 82.5 
Extra-Pulmonary Present j 1 2.5 k 10.0 
Tuberculosis 
Absent 39 97.5 36 90*0 
o Reactivated cases 
£ .Ci: aJ-UT 
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TABLE NO. 6 
COMPARISON OF EXTENT OF PULMONARY TUBERCULOSIS IN PATIENTS 
HAVING REACTIVATED PULMONARY TUVERCULOSIS AND CONTROLS. 
Study°Group Control Group 
Age in No, Min .(Pi) Mod.adv.(P9) Far-adv.(Po) Min (px) Mod.adv.(P?) Far-adv.(P-,) 
Years*- No. % No. % ~ No. % No. % No. % No. r 
< 30 3 1 2.3 2 3.0 0 0.0 0 0.0 2 5.0 1 2.5 
30-39 3 0 0.0 1 23o0 2 3.o 1 2,3 1 0,5 1 2.5 
ho -U9 3 1 2.3 3 7.3 2 3.0 1 2.5 3 7.5 1 2.5 
30-39 11 1 2.3 h 10.0 3 12.3 3 7.5 h 10.0 h 10.0 
> 60 18 3 12.3 10 23.0 3 7.3 3 7.5 10 25.0 5 12.5 
TOTALS UO 8 20.0 20 30.0 12 30.0 8 20.0 20 50.0 12 30.0 
•KAge determined at time of inactivity„ 
oReactivated cases. 
NOTE: 
P-j = Minimal pulmonary tuberculosis. 
?2 ~ Moderately advanced pulmonary tuberculosis. 
P^ = Far-advanced pulmonary tuberculosis. 
See Appendix I. 
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TABLE NO, 7 
COMPARISON OF BILATERAL AND UNILATERAL PULMONARY TUBERCULOSIS 




Patients with Bilateral 
Disease 


















< 30 3 0 0 : i 2.5 3 7.5 2 5.0 
30-39 3 1 2.5 i 2.5 2 5.0 2 5.0 
hO-h9 3 7.5 h 10.0 2 5.0 1 2.5 
50-59 11 9 22.5 7 17.5 2 5.0 h 10,0 I 
> 6q 18 12 30.0 lh 35.0 6 15.0 h X090 






*Age determined at time of inactivity, 
o Reactivated cases. 
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TABLE NO, 8 
COMPARISON OF PRESENCE OF CAVITATION OF PULMONARY PARENCHYMA 
IN PATIENTS HAVING REACTIVATED PULMONARY TUBERCULOSIS AND CONTROLS, 
Cavitation Present Cavitation not Present 
Age in No* Study0Group Control Group Study0Group Control Group 
Years*- No. <£ P No. % No. % No. % 
< 30 3 2 5.0 2 5.0 1 2.5 1 2.5 
30-39 3 3 7.5 2 5.0 0 0.0 1 2.5 
1*04*9 5 3 7.5 3 7.5 2 5.o 2 5.0 
50-59 11 5 12 o 5 5 12.5 6 i5.o 6 15.0 
> 60 18 7 17.5 7 17.5 11 27.5 11 27.5 
TOTALS 1*0 20 5o.o 19 1*7.5 20 5o„o 21 52.5 
*Age determined at time of inactivity 
o Reactivated cases. 
' 
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TABLE NO, 9 
COMPARISON OF MEAN WEIGHT GAIN DURING HOSPITALIZATION IN 





Average Weight Gain 
in Each Age Group 
in Stud/3 * 5 6Group (lbs.) 
No, 
Studied 
Average Weight Gain in 
Each Age Group in 
Control Group (lbs*) 





U.3 3 9.0 
U0-R9 h 12.2 9 22*2 
90-99 10 19.0 11 20*2 




33** 12 Jb 38** 20*1 
* Age determined at time of inactivity* 
No information was available for 7 study patients and 2 control patients* 
o Reactivated cases* 
NOTE: 
1) Mean weight gain in stud/5group 12*b lbs* 
control group 20*1 lbs* 
2) Observed difference 7.7 lbs* 
3) Standard deviation stud/5group 9.20 
control group 12.2b 
U) Standard error of the difference 2*97 
5) Observed difference/standard error of difference 7*70/2*97 E 3*00 
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TABLE NO. 10 
COMPARISON OF PERCENT OF SPUTUM POSITIVITY IN 











100 - 76% 25 62.5 35 87.5 
75 - 51% 7 17.5 3 7.5 
50 - 26% 5 12,5 2 5.0 
25 - 0% 1 2.5 0 0 
Not known 2 5.0 0 0 
TOTALS ho 100 ho 100 
o Reactivated cases» 
NOTE; 
It is assumed that the 2 unknown patients in study0group 
are> 75% positivity. 
Percentage of study°and control patients with percent of 
sputum positivity of less than 75%* 
Study°patients 32 <>5% 
Control patients 12*5% 
Standard error of the difference - 9.1 
Observed difference/standard error of difference 20.0/9.1 - 2.19 
P value = .03 is statistically significant. 
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TABLE NO. 11 
CONDITIONS FOR HOSPITAL DISCHARGE IN PATIENTS HAVING 
REACTIVATED PULMONARY TUBERCULOSIS AND CONTROLS» 
1 Condition for 
Hospital Discharge 
Study0Group j Control Group 
No, % No, % 
Maximum hospital 
benefit (MHB) 35 87 .5 3h 85.0 
Personal reasons 
with consent 1 2*5 3 7.5 
Personal reasons 
without consent 3, 7.5 0 0 
Against medical 
advice (AMA) 0 0 2 5.0 
Absent without 
leave (AWOL) . 1 2:. 5 
Disciplinary .  1 2.s 0 0 
TOTALS 
111 " — 
ho 100 hO 100_j 
o Reactivated cases 
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TABLE NO. 12 
COMPARISON OF DISEASE ACTIVITY AT TIME OF DISCHARGE 




Patients with Inactive 
Disease at Time of 
Discharge 
Patients with Active 
Disease at Time of 
Discharge 
Study°Group Control Group 
Patients Patients 
Study0Group Control Group 
Patients Patients 
No. nr No. I % I No. % No. % 
30 3 2 5.0 1 2.5 1 2.5 2 5.0 
30-39 3 1 2.5 3 7.5 2 5.0 0 0 
U0-U9 5 1 2.5 a 10.0 h 10.0 1 2.5 
50-59 ll 7 17.5 3 7.5 • a 10.0 8 20.0 
> 60 18 8 20.0 5 12.5 10 25.0 13 32.5 
TOTALS Uo 
” 1 17.5 16 ao.o 1 21 52.5 2h 60.0 
* Age determined at time of inactivity. 
° Reactivated cases 
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TABLE NO. 13 
COMPARISON OF PATIENTS WITH INACTIVE DISEASE AT DISCHARGE AND 
THE CONTINUATION OF CHEMOTHERAPY IN PATIENTS HAVING REACTIVATED PULMONARY TUBER¬ 
CULOSIS AND CONTROLS. 
1- "■ 
1 Age in 
Years* 
No. 
Patients Inactive at Discharge 
with Continued Chemotherapy 
Patients Inactive at Discharge • 
| without Further Chemotherapy j 
Study°Group Control Group Study* Group Control Group 
No. % No © A> No. IT No. | % 
< 30 3 1 2.5 0 1 2.5 1 2.5 
! 
30-39 3 0 0 0 0 1 2.5 3 2.5 
U0-U9 5 1 2.5 1 2.5 0 0 3 7.5 
50-59 11 h 10.0 1 2.5 3 7.5 2 5.0 
> 60 18 7 17.5 2 5»o 1 2.5 3 7.5 
| TOTALS UO 13 32.5 h 10.0 6 15.0 12 30.0 
#Age determined at time of inactivity, 
o Reactivated cases. 
NOTE: 
Patients inactive at discharge without further chemotherapy: 
Stud/* patients 36.5$ of 19 patients 
Control patients 75.0$ of 16 patients 
SEE TABLE 13 A 
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TABLE 13A 
CHI SQUARE CALCULATIONS FOR DIFFERENCES 
OBSERVED IN TABLE 13 
Inactive Patients at 
Discharge without 
further Chemotherapy 
Inactive Patients at 





6 13 19 
Control 
Group 12 a 16 
TOTALS 18 17 35 
% = 35 :l2U - 156 I - 17.5] 2 - = JUo93 
.(iB) a7nj6TT^')." 93j02U 
P Value result « 902<-P < ,05 is statistically significant. 
The statistical significance of the difference between these percentages 
was tested by the chi-square test with a correction for continuity. The 
usual test used in the other tables was not used here because of the smaller 
number on which these percentages xtere based. 
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APPENDIX I 
EXTENT OF DISEASE 
Extent of disease is determined by radiologic examination and is 
classified as minimal, moderately advanced, or far-advanced in accordance 
to the standards of the National Tuberculosis Association, 
1) Minimal♦ Minimal lesions include those which are of slight to 
moderate density but which do not contain demonstrable cavitation. They 
may involve a small part of one or both lungs but the total extent, regardless 
of distribution, should not exceed the volume of lung on one side which is 
present above the second chondrocostal junction and the spine of the fourth 
or the body of the fifth thoracic vertebrae* 
2) Moderately Advanced. Moderately advanced lesions may be present 
in one or both lungs, but the total extent should not exceed the following 
limits: disseminated lesions of slight to moderate density which may ex¬ 
tend throughout the total volume of one lung, or the equivalent in both 
lungs; dense and confluent lesions which are limited in extent to 
one-third the volume of one lung; total diameter of cavitation, if present, 
must be less than it cm, 
3) Far-advanced. This term is used to describe lesions which are 
more extensive than moderately advanced. 
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APPENDIX II 
ACTIVITY STATUS 
The stages of activity of pulmonary tuberculosis are based largely on 
roentgenographic and bacteriologic factors, and their duration. Disease is 
classified as active, quiescent, or inactive in accordance to the standards 
of the National Tuberculosis Association, 
1) Active., 
Bacteriologic: Tubercle bacilli demonstrated by any method in the 
sputum, gastric aspirates, or tracheal aspirates denote active tubercu¬ 
losis, 
Roengenographic: An active status exists if the probability of 
change is obvious on examination of a single chest x-ray, or if change 
for better or worse is demonstrable on serial x-rays at intervals of six 
months or less. The presence of tuberculous empyema, bronchopleural 
fistula, or active endobronchial tuberculosis requires that associated 
pulmonary tuberculosis be considered as active» 
2) Quiescent, 
This term requires negative bacteriologic findings and stable or im¬ 
proving lesions visible by x-ray but it allows the presence of cavitation, 
Bacteriologic examination must be negative for six months. This category 
includes the "open negative" lesions which are now being seen with increas¬ 
ing frequency, 
3) Inactive. 
The bacteriologic test must be negative by all methods for at least 
6 months. The x-ray examination must also be stable for at least six 
months, and no cavitation may be present. The required period of negative 
■ 
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bacteriologic status and the duration of stable, non-cavitary, radio- 
logic findings coincide, but the classification of inactive cannot be used 
until both have been present for six months* 
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APPENDIX NO. Ill 
STATISTICAL METHODS 
I. DIFFERENCES BETWEEN MEANS 
1) Calculation of Standard Deviations 
X = individual observation 
X = mean of this observation 
N = number of observations 
Through the following relationships,the standard deviation is calculated 
Sum (X - X)2 = Sum X2 - (Sum X)2 / N 
Standard deviation V Sum X2 - (Sum X)2 / N N-i 
2) Calculation of standard, error of this difference between means: 
S = study group 
C = control 
Standard error of the difference - \ (ST*DEV ) + 
•/ N, 
(ST ..DEVc) 
3) Z = observed difference/calculated standard error of difference 
The value of Z is referred to tables of area under the normal 
curve for corresponding P-values* 
h) P Value 
The area under the normal curve for values of Z equal to or 
greater than the value observed^ disregarding sign* 
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II, DIFFERENCES BETWEEN PROPORTIONS 
1) Calculation of standard error of the differences between 
proportions: 
p = percentage in the universe in one category, 
i* e., having a property* 
q = percentage in the universe in the other category, 
i. e.t not having that prooerty. 
Standard error of the difference -\ /p x q + p x q 
V Ns Nc 
Ns - number in study group 
Nc - number in control group 
2) Z - observed difference/calculated standard error of difference. 
Same as in differences between means* 
3) P Value Same as in differences between means* 
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